FHTX Logo

Foghorn Therapeutics Inc. (FHTX) 

NASDAQ
Market Cap
$285.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
667 of 960
Rank in Industry
371 of 550

Largest Insider Buys in Sector

FHTX Stock Price History Chart

FHTX Stock Performance

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; …

Insider Activity of Foghorn Therapeutics Inc.

Over the last 12 months, insiders at Foghorn Therapeutics Inc. have bought $0 and sold $853,289 worth of Foghorn Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Foghorn Therapeutics Inc. have bought $4.89M and sold $1.71M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 150,000 shares for transaction amount of $2.4M was made by Flagship Ventures Fund V General Partner LLC (10 percent owner) on 2020‑10‑27.

List of Insider Buy and Sell Transactions, Foghorn Therapeutics Inc.

2024-09-23SaleChief People Officer
857
0.0017%
$10.17$8,716-16.95%
2024-09-20SaleChief People Officer
35,756
0.0649%
$10.04$358,990-22.32%
2024-09-18SaleChief People Officer
11,574
0.022%
$10.05$116,319-18.57%
2024-09-17SaleChief People Officer
10,272
0.0189%
$10.04$103,131-20.83%
2024-09-16SaleChief People Officer
400
0.0008%
$10.00$4,000-15.66%
2024-09-09SaleChief Scientific Officer
20,000
0.0366%
$9.50$190,000-16.22%
2024-03-11SaleChief Strategy/Bus Ops Officer
11,000
0.0249%
$6.56$72,134-4.95%
2023-08-16SaleChief Medical Officer
311,297
0.6823%
$8.25$2.57M-35.39%
2020-10-27Purchase10 percent owner
150,000
1.3579%
$16.00$2.4M-20.50%
2020-10-27Purchase
150,000
1.3579%
$16.00$2.4M-20.50%
2020-10-27PurchaseChief Scientific Officer
5,500
0.0498%
$16.00$88,000-20.50%

Insider Historical Profitability

<0.0001%
Flagship Ventures Fund V General Partner LLC10 percent owner
9330878
16.7842%
$5.1410<0.0001%
Abu Dhabi Investment Authority
1231081
2.2144%
$5.1410<0.0001%
DECICCO CARLChief Scientific Officer
258397
0.4648%
$5.1410<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Flagship Pioneering$85.04M22.9112.67M0%+$05.58
Fidelity Investments$18.06M4.862.69M-4.23%-$797,637.81<0.01
Raymond James Associates$14.97M4.032.23M+7.84%+$1.09M0.01
Euclidean Capital Llc$10.56M2.841.57M0%+$01.36
BlackRock$8.83M2.381.32M+0.73%+$63,765.13<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.